Brian A. Van Tine
布莱恩·范·泰因
MD, PhD
Associate Professor of Medicine and Neurology; Director, Adult Sarcoma Program
👥Biography 个人简介
Brian A. Van Tine, MD, PhD is Associate Professor of Medicine and Neurology at Washington University School of Medicine in St. Louis and Director of the Adult Sarcoma Program at Siteman Cancer Center. He is an internationally recognized leader in translational sarcoma research with a particular focus on metabolic reprogramming in soft tissue sarcomas, NY-ESO-1-directed cell therapy, and the biology of synovial sarcoma. His dual training in medicine and biochemistry underlies a distinctive research program bridging fundamental cancer metabolism to clinical translation. Dr. Van Tine is known for pioneering studies demonstrating that sarcomas harboring SS18-SSX fusions (synovial sarcoma) are exquisitely dependent on non-oxidative glycolysis, and for early-phase clinical trials of NY-ESO-1-directed T-cell receptor engineered T cell (TCR-T) therapy in synovial sarcoma. He has authored over 160 peer-reviewed publications and is a sought-after speaker at national and international sarcoma meetings.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Metabolic Reprogramming in Synovial Sarcoma
Identified that SS18-SSX fusion-driven synovial sarcoma cells are uniquely dependent on non-oxidative glucose metabolism, demonstrating that PKM2 expression and pentose phosphate pathway activity confer a metabolic vulnerability exploitable with 2-deoxyglucose and related agents.
NY-ESO-1 TCR-T Cell Therapy in Sarcoma
Led and co-designed early-phase trials of NY-ESO-1-specific T-cell receptor engineered T cells in synovial sarcoma and myxoid/round cell liposarcoma, demonstrating objective responses and durable remissions in these NY-ESO-1 high-expressing sarcoma subtypes and establishing a foundation for adoptive cell therapy in sarcoma.
Olaratumab Clinical and Translational Investigation
Contributed translational correlative studies to the olaratumab clinical program, investigating PDGFRα biology, stroma remodeling, and biomarkers of response in the phase II and phase III ANNOUNCE trials of olaratumab in soft tissue sarcoma.
Sarcoma Immunotherapy: Overcoming Immune Exclusion
Characterized the immunosuppressive tumor microenvironment of synovial sarcoma, identifying TGF-β and EZH2-mediated immune exclusion mechanisms, and developed preclinical and clinical strategies to convert "cold" synovial sarcoma into immunologically inflamed tumors responsive to checkpoint blockade.
Representative Works 代表性著作
SS18-SSX2 Fusion Protein Induces Epigenetic Gene Regulation
PLoS ONE (2014)
Mechanistic study demonstrating how the SS18-SSX2 fusion protein drives global epigenetic reprogramming in synovial sarcoma, establishing links between fusion-driven chromatin remodeling and metabolic dependencies.
Adoptive Cell Therapy with Autologous NY-ESO-1 Reactive T Cells for Synovial Sarcoma
Annals of Oncology (2018)
Phase I/II trial demonstrating objective responses and durable remissions with NY-ESO-1-specific TCR-T cell therapy in synovial sarcoma, establishing adoptive cell therapy as a promising approach in this cancer-testis antigen high-expressing subtype.
TGF-β Mediates Immune Evasion in Synovial Sarcoma
Journal of Clinical Investigation (2021)
Demonstration that TGF-β secretion drives T-cell exclusion from synovial sarcoma and that TGF-β blockade synergizes with checkpoint inhibition to promote anti-tumor immunity in preclinical models.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 布莱恩·范·泰因 的研究动态
Follow Brian A. Van Tine's research updates
留下邮箱，当我们发布与 Brian A. Van Tine（Washington University School of Medicine in St. Louis）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment